Javascript must be enabled to continue!
SINGLE NUCLEOTIDE POLYMORPHISMS IN TGF-Β1 AND THEIR ASSOCIATION WITH HCC DEVELOPMENT IN HCV PATIENTS
View through CrossRef
Background: Hepatitis C virus (HCV) infection remains a global public health concern, affecting over 170 million individuals and contributing substantially to the burden of liver-related morbidity and mortality. Chronic HCV infection can progress to fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Cytokine gene polymorphisms, including transforming growth factor-beta 1 (TGF-β1), may influence individual susceptibility to HCC. Variations in the TGF-β1 promoter region, such as the −509 C/T polymorphism, can alter cytokine expression and potentially affect disease progression.
Objective: To investigate the association between TGF-β1 −509 C/T gene polymorphism and the risk of developing HCC in patients with chronic HCV infection in a local Pakistani population.
Methods: A comparative study was conducted involving 80 patients recruited from Sheikh Zayed Hospital, Lahore. Group I comprised 40 patients with chronic HCV infection without HCC, and Group II included 40 chronic HCV patients with HCC. Diagnosis of HCC was confirmed by abdominal ultrasound and computed tomography. Genotyping of TGF-β1 −509 C/T polymorphism was performed using polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP) analysis. Statistical analysis was conducted using SPSS version 20.0, with chi-square tests to assess genotype and allele distribution. Odds ratios (OR) with 95% confidence intervals (CI) were calculated, and p < 0.05 was considered significant.
Results: The TT genotype was present in 11 (39.3%) HCV patients and 17 (60.7%) HCC patients [OR = 2.511, 95% CI: 0.786–8.029, p = 0.120], while the CT genotype was detected in 16 (53.3%) HCV patients and 14 (46.7%) HCC patients [OR = 1.422, 95% CI: 0.457–4.427, p = 0.544]. No statistically significant association was observed between genotype distribution and HCC; however, individuals carrying the TT genotype or T allele exhibited a higher OR compared to those with the CC genotype.
Conclusion: Although no significant association was found, the TGF-β1 −509 T allele may contribute to increased susceptibility to HCC in chronic HCV patients in the local population, highlighting the need for larger-scale studies.
Health and Research Insights
Title: SINGLE NUCLEOTIDE POLYMORPHISMS IN TGF-Β1 AND THEIR ASSOCIATION WITH HCC DEVELOPMENT IN HCV PATIENTS
Description:
Background: Hepatitis C virus (HCV) infection remains a global public health concern, affecting over 170 million individuals and contributing substantially to the burden of liver-related morbidity and mortality.
Chronic HCV infection can progress to fibrosis, cirrhosis, and hepatocellular carcinoma (HCC).
Cytokine gene polymorphisms, including transforming growth factor-beta 1 (TGF-β1), may influence individual susceptibility to HCC.
Variations in the TGF-β1 promoter region, such as the −509 C/T polymorphism, can alter cytokine expression and potentially affect disease progression.
Objective: To investigate the association between TGF-β1 −509 C/T gene polymorphism and the risk of developing HCC in patients with chronic HCV infection in a local Pakistani population.
Methods: A comparative study was conducted involving 80 patients recruited from Sheikh Zayed Hospital, Lahore.
Group I comprised 40 patients with chronic HCV infection without HCC, and Group II included 40 chronic HCV patients with HCC.
Diagnosis of HCC was confirmed by abdominal ultrasound and computed tomography.
Genotyping of TGF-β1 −509 C/T polymorphism was performed using polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP) analysis.
Statistical analysis was conducted using SPSS version 20.
0, with chi-square tests to assess genotype and allele distribution.
Odds ratios (OR) with 95% confidence intervals (CI) were calculated, and p < 0.
05 was considered significant.
Results: The TT genotype was present in 11 (39.
3%) HCV patients and 17 (60.
7%) HCC patients [OR = 2.
511, 95% CI: 0.
786–8.
029, p = 0.
120], while the CT genotype was detected in 16 (53.
3%) HCV patients and 14 (46.
7%) HCC patients [OR = 1.
422, 95% CI: 0.
457–4.
427, p = 0.
544].
No statistically significant association was observed between genotype distribution and HCC; however, individuals carrying the TT genotype or T allele exhibited a higher OR compared to those with the CC genotype.
Conclusion: Although no significant association was found, the TGF-β1 −509 T allele may contribute to increased susceptibility to HCC in chronic HCV patients in the local population, highlighting the need for larger-scale studies.
Related Results
The Impact of IL28B Gene Polymorphisms on Drug Responses
The Impact of IL28B Gene Polymorphisms on Drug Responses
To achieve high therapeutic efficacy in the patient, information on pharmacokinetics, pharmacodynamics, and pharmacogenetics is required. With the development of science and techno...
T cell responses from blood donors infected with different HCV genotypes against HCV 1a proteins
T cell responses from blood donors infected with different HCV genotypes against HCV 1a proteins
Hepatitis C virus (HCV) infection, which can cause chronic liver diseases, cirrhosis and hepatocellular carcinoma, is still a major public health problem worldwide. Upon comparing ...
INFLUENCE OF HOST AND VIRAL FACTORS IN HEPATITIS C VIRUS INFECTION: ROLE OF TA REPEAT, IFNL3 AND IFNL4 POLYMORPHISMS IN HCV INFECTION AND OUTCOME OF TREATMENT
INFLUENCE OF HOST AND VIRAL FACTORS IN HEPATITIS C VIRUS INFECTION: ROLE OF TA REPEAT, IFNL3 AND IFNL4 POLYMORPHISMS IN HCV INFECTION AND OUTCOME OF TREATMENT
Hepatitis C virus (HCV) is a serious public health problem affecting 170 million carriers worldwide. It is a leading cause of chronic hepatitis, cirrhosis, and liver cancer and is ...
Abstract 4706: Gene and protein expression of TGF-beta signaling pathway molecules in women undergoing reduction mammoplasty
Abstract 4706: Gene and protein expression of TGF-beta signaling pathway molecules in women undergoing reduction mammoplasty
Abstract
Gene and protein expression of TGF-beta signaling pathway molecules in women undergoing reduction mammoplasty.
Introduction: The TGF- β signa...
Outcomes after curative treatment for cryptogenic cirrhosis‐associated hepatocellular carcinoma satisfying the Milan criteria
Outcomes after curative treatment for cryptogenic cirrhosis‐associated hepatocellular carcinoma satisfying the Milan criteria
AbstractBackground and Aim: The prognosis of cryptogenic cirrhosis‐associated hepatocellular carcinoma (CC‐HCC) was reported to be poor because many of them were discovered at the...
Single Nucleotide Polymorphisms in TGF-β1 and Their Association with HCC Development in HCV Patients
Single Nucleotide Polymorphisms in TGF-β1 and Their Association with HCC Development in HCV Patients
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality globally, with chronic hepatitis C virus (HCV) infection serving as a principal risk facto...
The role of hepatitis C virus genotypes and core mutations in hepatocellular carcinoma in Cameroon
The role of hepatitis C virus genotypes and core mutations in hepatocellular carcinoma in Cameroon
AbstractBackgroundHepatitis C virus (HCV) infection is known to be an important risk factor for hepatocellular carcinoma (HCC) in Cameroon. However, the effect of HCV‐related facto...
Setting the Record Straight: Utility and Outcomes in Patients With
HCV
Related
HCC
Setting the Record Straight: Utility and Outcomes in Patients With
HCV
Related
HCC
ABSTRACT
The effectiveness of direct acting antiviral (DAA) therapy in patients with active hepatocellular carcinoma (HCC) is poorly defined....

